Marc Hedrick, M.D., President and CEO of Plus Therapeutics (Nasdaq: PSTV), recently traveled to the New York Stock Exchange (NYSE) to join Remy Blaire of FINTECH.TV for an in-depth discussion on the company’s National Coverage Agreement with UnitedHealthcare Insurance Company (NYSE: UNH) for the CNSide® Cerebrospinal Fluid (CSF) Assay.

This milestone provides expanded access to the CNSide® CSF Tumor Cell Enumeration laboratory-developed test (LDT) — an advanced diagnostic platform for leptomeningeal metastases (LM) and other central nervous system (CNS) cancers — to more than 51 million UnitedHealthcare members nationwide.

“This agreement represents a major step forward for patients and physicians managing leptomeningeal metastases,” said Marc Hedrick, M.D. “National coverage by UnitedHealthcare makes CNSide® testing more accessible and underscores its clinical utility in improving diagnosis, treatment monitoring, and therapy planning.”

Expanding Access to Precision Diagnostics

CNSide® is a proprietary, highly sensitive CSF assay platform performed in a CLIA-accredited laboratory. It empowers clinicians to:

• Detect tumor cells in the cerebrospinal fluid earlier and more accurately
• Monitor disease progression and treatment response in real time
• Inform targeted therapy decisions for patients with LM and other CNS cancers

The UnitedHealthcare national coverage agreement validates the clinical value of CNSide® while supporting broader adoption of precision diagnostics across the U.S.

Watch the Full Interview

Watch Marc Hedrick, M.D., on FINTECH.TV: View on YouTube →
Learn more about CNSide® Diagnostics: CNSide Official Website
Investor Relations — Plus Therapeutics (Nasdaq: PSTV): Visit IR Site →

#PlusTherapeutics #CNSide #LeptomeningealMetastases #LeptomeningealCancer #PrecisionDiagnostics #NeuroOncology #HealthcareInnovation #UnitedHealthcare #PSTV #NYSE #FINTECHTV